Heparin-induced thrombocytopenia (HIT)

Question

What are the consensus guidelines for platelet count monitoring for patients at risk of heparin induced thrombocytopenia?

Answer

The American College of Chest Physicians and the College of American Pathologists have published guidelines for platelet count monitoring in patients at risk of HIT. For patients with recent heparin exposure or who are starting unfractionated heparin or low molecular weight heparin, a baseline platelet count should be obtained and repeated within 24 hours of starting heparin. Patients receiving unfractionated heparin at therapeutic doses should have their platelet count monitored at least every 2 days until day 14 of treatment or until unfractionated heparin is stopped, whichever comes first. Postoperative patients receiving unfractionated heparin antithrombotic prophylaxis should have their platelet count monitored at least every 2 days between postoperative days 4 and 14, or until unfractionated heparin is stopped. Medical and obstetric patients receiving prophylactic-dose unfractionated heparin, or low molecular weight heparin after first receiving unfractionated heparin, or postoperative patients receiving prophylactic dose low molecular weight heparin , or intravascular catheter unfractionated heparin flushes should have their platelet count monitored every 2 or 3 days from days 4 to 14 or until unfractionated heparin is stopped. Medical and obstetric patients receiving only low molecular weight heparin , or medical patients receiving catheter unfractionated heparin flushes should be monitored as clinically indicated with no routine monitoring.

Question

Why is warfarin not recommended in the early stage of HIT?

Answer

Warfarin is not recommended in the early stage of HIT because it can paradoxically worsen the thrombosis and cause venous limb gangrene and skin necrosis. This is due to an imbalance between the natural anticoagulant and procoagulant proteins associated with HIT-related consumption, which are exacerbated during warfarin induction.

Question

What are the non-heparin anticoagulants available for alternative anticoagulation in HIT, and how are they monitored?

Answer

The three non-heparin anticoagulants that do not crossreact with HIT antibodies are danaparoid, lepirudin, and argatroban. Danaparoid and lepirudin are available for use in the UK, while argatroban is used in North America. These drugs are immediately active and are direct inhibitors of thrombin. They also inhibit thrombin generation and are monitored using the activated partial thromboplastin time (aPTT), activated clotting time (ACT) for argatroban, ecarin clotting time (ECT) for lepirudin, or anti-Xa assays for danaparoid. When choosing an alternative anticoagulant, consideration should be given to its demonstrated efficacy and safety in the intended use, likely risks and benefits of treatment strategies, availability of the drug and methods for monitoring, and the patient’s clinical status, including renal and hepatic function.

Question

What role does Aspirin play in the treatment of HIT?

Answer

Aspirin may have some clinical benefit in the treatment of HIT, but it is not considered a frontline treatment because it lacks direct anticoagulant effects and does not inhibit F c receptor-mediated activation of platelets by HIT antibody.

Question

What are the recommended guidelines for monitoring platelet count in patients at high risk for HIT?

Answer

The American College of Chest Physicians, in collaboration with the College of American Pathologists, have published guidelines for monitoring platelet count in patients at high risk for HIT (Heparin-Induced Thrombocytopenia). These guidelines recommend a baseline platelet count before initiating heparin treatment in all patients to allow estimation of relative changes. In higher risk patients, such as individuals receiving unfractionated heparin at therapeutic doses, the platelet count should be checked at least every other day from day 4 to 14 of treatment (or until heparin is stopped, whichever is sooner). In lower risk surgical, medical, and obstetric patients, monitoring should be at least on every second to fourth day between days 4 and 14 while on heparin treatment. Obstetric patients receiving prophylactic doses of low molecular weight heparins do not need routine platelet monitoring.

Question

What is the main safety concern with direct thrombin inhibitors as anticoagulant treatment?

Answer

Bleeding is the main safety concern with direct thrombin inhibitors because no specific antidotes are available and protamine sulfate only negligibly neutralises danaparoid.

Question

How does the short half-life of argatroban benefit patients with HIT?

Answer

Argatroban has the shortest half-life among all alternative anticoagulants, making it easy to discontinue quickly if needed, such as in the event of bleeding or when invasive procedures are necessary during HIT treatment.

Question

What is danaparoid?

Answer

Danaparoid is a mixture of heparin, dermatan, and chondroitin sulfates that exerts its anticoagulant effects predominantly by inhibiting factor 10 A and to a much lesser degree by inhibiting thrombin.

Question

What factors contribute to the incidence of HIT, and how do they differ between heparin types and patient populations?

Answer

In general, the incidence of HIT is greater with bovine heparin compared to porcine heparin, although all heparins used in the UK are of porcine origin. The incidence is also higher with unfractionated heparin compared to low molecular weight heparins, although it should be noted that antibodies developing in patients receiving unfractionated heparins frequently crossreact with low molecular weight heparins. Furthermore, post-surgical patients, particularly those undergoing cardiac, orthopaedic, vascular, or general surgery, are more likely to develop HIT than medical or obstetric patients, with an incidence of 0.8%.

Question

What percentage of patients receiving heparin are at risk of developing HIT antibodies, and how many of them may progress to develop HIT with thrombocytopenia?

Answer

Up to 8% of patients receiving heparin are at risk of developing HIT antibodies. However, only 1-5% of patients receiving heparin will progress to develop HIT with thrombocytopenia. Subsequently, one-third of those patients may suffer from arterial and/or venous thrombosis.

Question

Why is heparin-PF4 antibody testing recommended in patients with clinical suspicion of HIT?

Answer

Heparin-PF4 antibody testing is recommended in patients with clinical suspicion of HIT (Heparin-Induced Thrombocytopenia) because it can help confirm the diagnosis of HIT. The presence of heparin-PF4 antibodies in the blood is a key indicator of HIT.

Question

What is the half-life of recombinant hirudin and how is it excreted?

Answer

Recombinant hirudin has a half-life of 60-90 minutes and is excreted through renal excretion.

Question

What is the proposed change to the terminology of HIT?

Answer

It has been proposed that the term "HIT type 1” be changed to "non-immune heparin-associated thrombocytopenia" and that the term "HIT type 2” be changed to "HIT" to avoid confusion between the two syndromes.

Question

What are low molecular weight heparins and how are they produced?

Answer

Low molecular weight heparins are a class of anticoagulant drugs that have a molecular weight ranging from 2000 to 10000 Daltons. They are derived from unfractionated heparins through chemical or enzymatic processes. The process of producing Low molecular weight heparins involves breaking down the longer chains of unfractionated heparins into smaller fragments, resulting in a more consistent and predictable molecule size. This also allows for Low molecular weight heparins to have a more predictable dose-response relationship compared to unfractionated heparins, making it a preferred choice for many clinical applications.

Question

How does heparin-PF4 complex formation lead to the development of heparin-induced thrombocytopenia?

Answer

When heparin binds with platelet factor 4 (PF4), it undergoes a conformational change and becomes immunogenic, leading to the generation of heparin-PF4 antibodies, most frequently of the IgG class. The resulting heparin-PF4-IgG multimolecular immune complex can then activate platelets via their Fc gamma 2a receptors, causing the release of prothrombotic platelet-derived microparticles, platelet consumption, and thrombocytopenia. These microparticles can also promote excessive thrombin generation, frequently resulting in thrombosis. In addition, the antigen-antibody complexes can interact with monocytes, leading to tissue factor production, and antibody-mediated endothelial injury may occur, contributing further to the activation of the coagulation cascade. Overall, the development of HIT is a complex process involving multiple factors, including the interaction between heparin and PF4, the generation of antibodies, and the subsequent activation of platelets and other cells involved in the coagulation pathway.

Question

Which organ impairment increases the half-life of lepirudin?

Answer

Renal impairment increases the half-life of lepirudin.

Question

Why is it important not to delay proper treatment for HIT while waiting for laboratory test results?

Answer

It is important not to delay proper treatment for HIT (Heparin-Induced Thrombocytopenia) while waiting for laboratory test results because HIT can be a life-threatening condition. Delaying treatment can increase the risk of serious complications. Therefore, treatment should begin immediately based on the patient's clinical presentation, without waiting for laboratory confirmation of HIT. The laboratory results can then be used to confirm the diagnosis and guide ongoing treatment.

Question

What is the mortality rate associated with thrombosis in heparin-induced thrombocytopenia?

Answer

Thrombosis in HIT is associated with a mortality rate of approximately 20-30%. Additionally, an equal percentage of patients become permanently disabled by amputation, stroke, or other causes.

Question

What are some other causes of thrombocytopenia?

Answer

There are several other causes of thrombocytopenia, including viral infections such as HIV, hepatitis C, and Epstein-Barr virus, autoimmune disorders such as lupus and rheumatoid arthritis, medication side effects, such as chemotherapy and certain antibiotics, alcoholism, bone marrow disorders, and genetic conditions such as Wiskott-Aldrich syndrome. Additionally, pregnancy-related conditions such as gestational thrombocytopenia and pre-eclampsia can also cause thrombocytopenia.

Question

What is the "4 T's" scoring system used for estimating the pre-test probability of heparin-induced thrombocytopenia?

Answer

The "4 T's" scoring system is used to estimate the pre-test probability of heparin-induced thrombocytopenia. It assigns points based on four categories: Thrombocytopenia, Timing of platelet count fall, Thrombosis or other sequelae, and Other cause for thrombocytopenia. The scoring system categorizes the probability of HIT into three levels: "Possible" (score of 0-3), "Intermediate" (score of 4-5), and "Definite" (score of 6 or greater). The categories within each of the four categories are assigned different point values.

Question

What is the recommended dose of Lepirudin for HIT patients without thrombosis?

Answer

The recommended dose for HIT patients without thrombosis is 0.1 mg per kg per hour without a bolus.

Question

What is meant by mild and transient thrombocytopenia?

Answer

Mild and transient thrombocytopenia is defined as a platelet count rarely below 100000 per microliter.

Question

What is the advantage of using argatroban in patients with renal insufficiency?

Answer

A major advantage of argatroban is that it is cleared by the liver, making it a safer alternative anticoagulant in patients with renal insufficiency, where other anticoagulants may be difficult to clear through the kidneys.

Question

What are the criteria for diagnosing heparin-induced thrombocytopenia?

Answer

The criteria for diagnosing HIT include normal platelet count before the commencement of heparin, thrombocytopenia defined as a drop in platelet count by 30% to less than 100 x 10 to the power of 9, or a drop of >50% from the patient's baseline platelet count, onset of thrombocytopenia typically 5-10 days after initiation of heparin treatment (which can occur earlier with previous heparin exposure within 100 days), acute thrombotic event, exclusion of other causes of thrombocytopenia, resolution of thrombocytopenia after cessation of heparin, and HIT antibody seroconversion.

Question

Why is Lepirudin contraindicated in patients on haemodialysis or with acute renal failure?

Answer

Lepirudin is contraindicated in patients on haemodialysis or with acute renal failure because it may result in the formation of lepirudin-antibody complexes, which are too large for renal excretion, leading to increased plasma lepirudin concentrations and the need to reduce dose.

Question

What are the pharmacokinetic properties of danaparoid?

Answer

Danaparoid has a long half-life, near 100% bioavailability, and is cleared renally.

Question

What is the risk of anaphylaxis with Lepirudin use?

Answer

The risk of anaphylaxis with Lepirudin use is estimated to be 0.15% of patients on first exposure and 0.2% of patients upon re-exposure. Omitting the bolus dose may reduce the severity of anaphylaxis and non-hirudin anticoagulants should be considered for use in patients with previous lepirudin exposure.

Question

Does the type and site of thrombosis in heparin-induced thrombocytopenia vary among patients?

Answer

Yes, the type and site of thrombosis in HIT depend on the patient's clinical profile. For example, deep vein thrombosis and pulmonary embolism occur more frequently in postoperative patients, while the presence of a central venous catheter is associated with increased upper-extremity venous thrombosis. Thrombosis of the cerebral venous sinuses and disseminated intravascular coagulation has also been reported. Arterial thrombosis, on the other hand, occurs more frequently than venous thrombosis in HIT patients receiving heparin for cardiovascular diseases.

Question

What is the recommended initial dose of lepirudin for patients with thrombosis?

Answer

The recommended initial dose for patients with thrombosis is 0.4 mg per kg followed by a 0.15 mg per kg per hour infusion, adjusted to a P T T ratios of 1.5-2.5, corresponding to a lepirudin concentration of approximately 0.6-1.4 mg per liter.

Question

What is the risk of major hemorrhage associated with recombinant hirudin?

Answer

The risk of major hemorrhage is directly related to the a P T T ratio, lepirudin concentrations, and serum creatinine concentrations.

Question

What are the characteristics of HIT type 1?

Answer

HIT type 1 affects up to 10% of patients, usually occurs within the first 48–72 h after initiation of heparin treatment, and is characterised by a mild and transient thrombocytopenia. No laboratory tests are required to diagnose HIT type 1, and it is not associated with an increased risk of thrombosis.

Question

Is there any evidence of antibody generation to argatroban on prolonged or repeated administration?

Answer

No, there is no evidence of antibody generation to argatroban on prolonged or repeated administration.

Question

What factors should be considered when deciding on anticoagulation treatment for patients with a history of HIT, and is it acceptable to use an alternative anticoagulant to Unfractionated Heparin or low molecular weight heparin in these cases?

Answer

Anticoagulation treatment for patients with a history of HIT should be decided based on several factors, including the type of surgery, the urgency of the surgery, whether anticoagulation is required for therapeutic or prophylactic reasons, and whether the patient is HIT antibodies positive or negative. HIT antibodies are transient, with a median time to disappearance of 50-80 days. In the vast majority of cases (excluding cardiac and vascular), it is acceptable to use an anticoagulant alternative to unfractionated heparin or low molecular weight heparin in patients with a previous history of HIT who require a period of anticoagulation or anticoagulant prophylaxis, due to the potential devastating consequences of recurrent HIT. However, the specific choice of anticoagulant alternative should be made on a case-by-case basis by a healthcare professional with expertise in anticoagulation management.

Question

What are the general principles to be taken when HIT is suspected clinically?

Answer

When HIT is suspected clinically, the following measures should be taken: Immediate cessation of all formulations of heparin is mandatory, including heparin flushes, heparin-coated catheters, heparinised dialysate, and any other sources. Send blood samples for laboratory confirmation. Initiate alternative anticoagulation. The duration of treatment is not well defined; however, it should be continued for at least 2-3 months to prevent recurrence of thrombosis. Monitor carefully for thrombotic events. Monitor platelet count till recovery. Warfarin should not be used until the platelet count has recovered. Avoid prophylactic platelet transfusion because they may exacerbate the hypercoagulable state, leading to additional thrombosis. However, if the patient develops bleeding or is undergoing major surgical intervention, therapeutic platelet transfusion can be considered.

Question

What are the two types of HIT and how do they differ?

Answer

HIT may develop in two distinct forms: type 1 and type 2. HIT type 1 is a non-immunologic response to heparin treatment, while HIT type II is immunemediated and associated with a risk of thrombosis.

Question

What is the recommended initial dose of Argatroban?

Answer

The recommended initial dose of Argatroban is 2 mg per kg per min. This dose should be adjusted to achieve a P T T (activated partial thromboplastin time) 1.5 to 3 times the baseline value. This provides adequate anticoagulation for 90% of patients.

Question

What is the hospital-wide incidence of HIT in patients who received heparin for more than 4 days?

Answer

Hospital-wide surveillance studies conducted over 32-36 months suggest that HIT occurred in 1.2% of all patients who received heparin for more than 4 days.

Question

Which direct thrombin inhibitor has a long half-life that makes rapid reversal after drug discontinuation impossible?

Answer

Danaparoid has a long half-life (up to 25 h) that makes rapid reversal after drug discontinuation impossible. Haemodialysis or haemofiltration can sometimes reduce concentrations of lepirudin, but not argatroban.

Question

How can unintentional excessive anticoagulation associated with or without bleeding be managed with direct thrombin inhibitors?

Answer

Unintentional excessive anticoagulation associated with or without bleeding can be managed by stopping or reducing the dose of direct thrombin inhibitors. The anticoagulant effects decrease to baseline within hours in most cases, but may vary depending on the drug’s half-life and the patient’s organ function.

Question

What is HIT, and how is it related to heparin administration?

Answer

HIT, or Heparin-induced thrombocytopenia, is a rare but potentially life-threatening condition that can occur following heparin administration. It is caused by the formation of antibodies that activate platelets, resulting in the formation of blood clots in the body.

Question

Why is routine monitoring of platelet count recommended for patients receiving heparin treatment?

Answer

Routine monitoring of platelet count is recommended for patients receiving heparin treatment because a drop in platelet count is a primary way of recognizing HIT (Heparin-Induced Thrombocytopenia).

Question

What percentage of patients may develop anti-hirudin antibodies after using Lepirudin?

Answer

Approximately 50% of patients may develop anti-hirudin antibodies that bind the drug to form lepirudin-antibody complexes

Question

What is the role of platelet Fc gamma 2a receptor polymorphism in heparin-induced thrombocytopenia?

Answer

Platelet Fc gamma 2a receptor polymorphism plays an important role in determining platelet reactivity, and different Fc gamma 2a phenotypes may be responsible for the variability in the risk of developing HIT.

Question

Why is low molecular weight heparin not recommended in patients with HIT?

Answer

Low molecular weight heparin cannot be used in patients with HIT due to the strong cross-reactivity of the HIT antibody with the Low molecular weight heparin-PF4 complex.

Question

What is the typical severity of thrombocytopenia in HIT, and what is the range of median platelet counts observed? Can thrombocytopenia in HIT be absolute or relative, and how is it characterized in terms of pre-heparin values?

Answer

The thrombocytopenia of HIT is typically of moderate severity, with median platelet counts ranging between 50-80 x 10^9 per Liter. It may be absolute, with platelet counts dropping below 150 platelets x 10^9 per Liter, or relative, with a drop of 50% or more compared with the pre-heparin value. However, the nadir, or lowest point, of platelet counts may remain above 150 x 10^9 per Liter.

Question

Are all patients who receive heparin at risk of developing heparin-induced thrombocytopenia?

Answer

Yes, patients of any age who receive any type of heparin at any dose by any route of administration are at risk of developing heparin-induced thrombocytopenia antibodies. However, not all patients who develop HIT antibodies will necessarily develop the clinical syndrome of HIT. It is important to distinguish between the frequency of antibody detection, which is common in patients receiving heparin, and the development of HIT, which is characterized by the formation of HIT antibodies along with thrombocytopenia and, often, thrombosis.

Question

When does the fall in platelet count typically begin in HIT, and how does the onset of thrombocytopenia vary based on previous heparin exposure? Is the onset of thrombocytopenia always rapid, or can it be delayed?

Answer

In HIT, the fall in platelet count typically starts between 5-14 days after initiation of heparin. However, the onset of thrombocytopenia can vary based on previous heparin exposure. If a patient has circulating heparin-PF4 antibodies from a recent heparin exposure, the platelet count may drop within minutes or hours, resulting in rapid-onset HIT. Conversely, in delayed-onset HIT, the thrombocytopenia is delayed for several days, possibly up to 3 weeks, and only becomes evident after heparin treatment has already been stopped.

Question

What is the risk of thrombotic events after discontinuing heparin treatment in patients with HIT?

Answer

The risk of thrombotic events after discontinuing heparin treatment in patients with HIT ranges from 5-10% per day in the first few days, increasing to 40-50% over the next several days or weeks.

Question

What is the in vitro crossreactivity of danaparoid to HIT sera (serum of patients with heparin-induced thrombocytopenia)?

Answer

Danaparoid exhibits in vitro crossreactivity to heparin-induced thrombocytopenia sera in about 10–50% of cases. In vivo crossreactivity of danaparoid to HIT sera is rare, although it has been well described and has been associated with unfortunate treatment failures.

Question

What are unfractionated heparins and how are they derived?

Answer

Unfractionated heparins are a type of anticoagulant medication that is derived from animal sources. Unfractionated heparin is a heterogenous mixture of negatively charged, sulfated glycosaminoglycan molecules that have a molecular weight ranging from 3000 to 30000 Daltons. These molecules are typically extracted from animal tissues such as the lungs and intestines of pigs or cows. Unfractionated heparin is a complex mixture of various chain lengths and molecular weights, which can result in variable pharmacokinetics and pharmacodynamics. Due to its heterogeneity, Unfractionated heparin requires careful monitoring and dosing to achieve the desired anticoagulant effect without increasing the risk of bleeding.